​

Aclaris Therapeutics (ACRS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

ACRS Stock Forecast

Aclaris Therapeutics (ACRS) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $10.75, with a high of $12.00 and a low of $10.00. This represents a 183.64% increase from the last price of $3.79.

$2 $4 $6 $8 $10 $12 High: $12 Avg: $10.75 Low: $10 Last Closed Price: $3.79

ACRS Stock Rating

Aclaris Therapeutics stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (81.25%), 3 Hold (18.75%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 3 13 Strong Sell Sell Hold Buy Strong Buy

ACRS Price Target Upside V Benchmarks

TypeNameUpside
StockAclaris Therapeutics183.64%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-16
Avg Price Target-$10.00$10.50
Last Closing Price$3.79$3.79$3.79
Upside/Downside-163.85%177.04%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 261101--12
Sep, 26191--11
Aug, 26181--10
Jul, 26191--11
Jun, 26181--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 01, 2026Edward NashCanaccord Genuity$10.00$6.0565.29%163.85%
May 05, 2026Biren AminPiper Sandler$11.00$4.53142.83%190.24%
May 05, 2026Guggenheim$12.00$4.53164.90%216.62%
Apr 29, 2026Martin FanWedbush$10.00$4.22136.97%163.85%
Apr 16, 2026UBS$10.00$3.93154.45%163.85%
Jan 30, 2026Adam VogelCraig-Hallum$10.00$3.43191.55%163.85%
Nov 19, 2024Julian HarrisonBTIG$8.00$3.14154.78%111.08%
Nov 19, 2024Roger SongJefferies$7.00$3.14122.93%84.70%
Nov 06, 2024Alex ThompsonStifel Nicolaus$3.00$2.2831.58%-20.84%
Dec 01, 2022Goldman Sachs$25.00$15.2264.26%559.63%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 31, 2026Piper SandlerOverweightOverweighthold
May 05, 2026Piper SandlerOverweightOverweighthold
May 05, 2026GuggenheimBuyinitialise
Apr 29, 2026WedbushOutperformOutperformhold
Apr 16, 2026OppenheimerOutperforminitialise
Jan 30, 2026Craig-HallumBuyinitialise
Jan 28, 2026CitigroupBuyBuyhold
Jan 06, 2026JefferiesBuyBuyhold
May 28, 2025WedbushOutperforminitialise

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.60$-1.33$-1.27$-1.71$-0.53---
Avg Forecast$-1.61$-1.44$-1.61$-0.82$-0.59$-0.65$-0.71$-0.59
High Forecast$-0.33$-0.31$-1.52$-0.57$-0.45$-0.49$-0.60$0.02
Low Forecast$-3.90$-3.76$-1.66$-1.12$-0.99$-0.94$-0.86$-1.28
Surprise %-0.62%-7.64%-21.12%108.54%-10.17%---

Revenue Forecast

$0 $17M $34M $51M $68M $85M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.76M$29.75M$31.25M$18.72M$7.83M---
Avg Forecast$7.05M$23.99M$18.34M$11.62M$11.97M$8.29M$6.96M$42.43M
High Forecast$14.78M$53.87M$24.25M$13.77M$21.72M$15.66M$13.14M$80.13M
Low Forecast$2.73M$9.48M$14.96M$10.06M$2.80M$1.74M$1.46M$8.90M
Surprise %-4.13%24.00%70.40%61.15%-34.63%---

Net Income Forecast

$-150M $-110M $-70M $-30M $10M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-90.86M$-86.91M$-88.48M$-132.06M$-64.92M---
Avg Forecast$-77.55M$-87.16M$-88.48M$-58.98M$-61.52M$-49.98M$-50.91M$-41.42M
High Forecast$-62.04M$-69.73M$-70.78M$-39.55M$-31.59M$-34.03M$-42.02M$1.13M
Low Forecast$-93.06M$-104.59M$-106.18M$-78.40M$-68.80M$-65.94M$-59.80M$-89.27M
Surprise %17.16%-0.28%-123.93%5.54%---

ACRS Forecast FAQ

Is Aclaris Therapeutics stock a buy?

Aclaris Therapeutics stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aclaris Therapeutics is a favorable investment for most analysts.

What is Aclaris Therapeutics's price target?

Aclaris Therapeutics's price target, set by 16 Wall Street analysts, averages $10.75 over the next 12 months. The price target range spans from $10 at the low end to $12 at the high end, suggesting a potential 183.64% change from the previous closing price of $3.79.

How does Aclaris Therapeutics stock forecast compare to its benchmarks?

Aclaris Therapeutics's stock forecast shows a 183.64% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Aclaris Therapeutics over the past three months?

  • October 2026: 8.33% Strong Buy, 83.33% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 9.09% Strong Buy, 81.82% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 10.00% Strong Buy, 80.00% Buy, 10.00% Hold, 0% Sell, 0% Strong Sell.

What is Aclaris Therapeutics’s EPS forecast?

Aclaris Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.65, marking a 22.64% increase from the reported $-0.53 in 2025. Estimates for the following years are $-0.71 in 2027, and $-0.59 in 2028.

What is Aclaris Therapeutics’s revenue forecast?

Aclaris Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $8.29M, reflecting a 5.99% increase from the reported $7.83M in 2025. The forecast for 2027 is $6.96M, and $42.43M for 2028.

What is Aclaris Therapeutics’s net income forecast?

Aclaris Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-49.984M, representing a -23.01% decrease from the reported $-64.923M in 2025. Projections indicate $-50.912M in 2027, and $-41.42M in 2028.